Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468170 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5517050 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL126194 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21547377 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL12344760 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Bromide SCHEMBL2542868 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1375642 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16645317 | 0.93 | HSD17B10 (0.47) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29299530 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL20686921 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2022269532-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022156793-A1 | QUINOXALINE-BASED D-A-D NEAR-INFRARED TWO-REGION FLUORESCENT MOLECULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-07-28 | — | — | WO | disclosed |
| EP-3222617-B1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022002022-A1 | RADIONUCLIDE LABEL AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-04-20 | — | — | US | disclosed |
| US-10758634-B2 | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography | WAKE FOREST UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-10696631-B2 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190084931-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | US HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-20190038785-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS USING ZIRCONIUM-89 IN IMMUNO-POSITRON EMISSION TOMOGRAPHY | WAKE FOREST UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3222617-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | The Johns Hopkins University (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2408755-B1 | Urea-based peptide compounds useful for detecting inter alia prostate cancer | UNIV JOHNS HOPKINS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084931-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | H1-4, VIP, H1-3 | HSD17B10 3363/4885MEN1 65/4885KMT2A 3799/4885 |
| US-10758634-B2 | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography | PAICS, IKZF2, ZRANB2 | HSD17B10 4812/4885MEN1 1146/4885KMT2A 677/4885 |
| US-20190038785-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS USING ZIRCONIUM-89 IN IMMUNO-POSITRON EMISSION TOMOGRAPHY | PAICS, IKZF2, ZRANB2 | HSD17B10 4812/4885MEN1 1146/4885KMT2A 677/4885 |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | HSD17B10 2398/4885MEN1 190/4885KMT2A 2318/4885 |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | RABL3, H1-4, SSTR3 | HSD17B10 3981/4885MEN1 217/4885KMT2A 3229/4885 |
| US-10696631-B2 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | H1-4, VIP, H1-3 | HSD17B10 3363/4885MEN1 65/4885KMT2A 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.